| 000 | 01513 a2200433 4500 | ||
|---|---|---|---|
| 005 | 20250516214410.0 | ||
| 264 | 0 | _c20141124 | |
| 008 | 201411s 0 0 eng d | ||
| 022 | _a1177-8881 | ||
| 024 | 7 |
_a10.2147/DDDT.S52428 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _adi Nuzzo, Luigi | |
| 245 | 0 | 0 |
_aMolecular pharmacodynamics of new oral drugs used in the treatment of multiple sclerosis. _h[electronic resource] |
| 260 |
_bDrug design, development and therapy _c2014 |
||
| 300 |
_a555-68 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 | _aAdministration, Oral |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aBlood-Brain Barrier _xdrug effects |
| 650 | 0 | 4 |
_aCrotonates _xpharmacology |
| 650 | 0 | 4 | _aDimethyl Fumarate |
| 650 | 0 | 4 | _aFingolimod Hydrochloride |
| 650 | 0 | 4 |
_aFumarates _xpharmacology |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aHydroxybutyrates |
| 650 | 0 | 4 |
_aImmune System _xdrug effects |
| 650 | 0 | 4 |
_aMultiple Sclerosis _xdrug therapy |
| 650 | 0 | 4 |
_aNF-E2-Related Factor 2 _xphysiology |
| 650 | 0 | 4 | _aNitriles |
| 650 | 0 | 4 |
_aPropylene Glycols _xpharmacology |
| 650 | 0 | 4 |
_aQuinolones _xpharmacology |
| 650 | 0 | 4 |
_aSphingosine _xanalogs & derivatives |
| 650 | 0 | 4 |
_aToluidines _xpharmacology |
| 700 | 1 | _aOrlando, Rosamaria | |
| 700 | 1 | _aNasca, Carla | |
| 700 | 1 | _aNicoletti, Ferdinando | |
| 773 | 0 |
_tDrug design, development and therapy _gvol. 8 _gp. 555-68 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.2147/DDDT.S52428 _zAvailable from publisher's website |
| 999 |
_c23869600 _d23869600 |
||